本文選題：型糖尿病 + GLP-受體激動(dòng)劑�。� 參考：《中國(guó)新藥雜志》2015年19期

【摘要】：當(dāng)前研究已經(jīng)顯示2型糖尿病同肥胖癥具有并發(fā)趨勢(shì),臨床上也公認(rèn)將控制患者體重列入到2型糖尿病治療指南中。目前在已經(jīng)過(guò)驗(yàn)證的治療方案中,只有胰高血糖素樣肽受體激動(dòng)劑(glucagon-like peptide-1 receptor agonists,GLP-1 RAs)可以實(shí)現(xiàn)對(duì)患者的體重和血糖水平同時(shí)調(diào)控。GLP-1作為GLP-1受體激動(dòng)劑研究的基礎(chǔ),具有血糖依賴性的促進(jìn)胰島素分泌作用。其可以通過(guò)抑制食欲和減緩胃排空來(lái)達(dá)到減輕體重的作用。天然的GLP-1由于受到二肽基肽酶(dipeptide peptidase,DPP-Ⅳ)的降解作用,半衰期僅為2 min。為了延長(zhǎng)GLP-1 RAs的體內(nèi)半衰期,多種改造策略被應(yīng)用于新型GLP-1受體激動(dòng)劑的研究開(kāi)發(fā),目前此類GLP-1受體激動(dòng)劑已部分進(jìn)入臨床評(píng)估階段,給藥頻率將從每周1次延長(zhǎng)到每月1次。本文將對(duì)近年來(lái)已進(jìn)入臨床試驗(yàn)研究的GLP-1受體激動(dòng)劑進(jìn)行綜述。
[Abstract]:Current studies have shown that type 2 diabetes has a tendency to be associated with obesity, and it is also recognized that weight control is included in the treatment guidelines for type 2 diabetes. At present, only glucagon-like peptide-1 receptor agonists, glucagon-like peptide-1 receptor agonistsGLP-1 RAsS, have been proven to be the basis for simultaneous regulation of body weight and blood glucose levels as GLP-1 receptor agonists. Promote insulin secretion in a glucose dependent manner. It can reduce weight by suppressing appetite and reducing gastric emptying. The natural GLP-1 was degraded by dipeptidyl peptidase (DPP- 鈪，

本文編號(hào)：1890874